Previous 10 | Next 10 |
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pha...
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $500 million of 5.150% Notes due 2029 (the “...
2024-06-02 17:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 13:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the most prominent ways to quiet the bears is to point to the performance of the S&P 500 . After all, this collection of 500 prominent U.S.-listed companies incorporates a divers...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20,...
2024-05-23 07:43:50 ET Summary Tenable's 1Q24 earnings beat expectations, with revenue of $216 million and strong profitability. The company's growth momentum remains strong, driven by demand in the enterprise market and the success of Tenable One. Tenable's valuation has been...
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced t...
2024-05-22 09:34:28 ET More on Rapid7 Rapid7 Inc. (RPD) Q1 2024 Earnings Call Transcript Rapid7: Positive Profitability Improvements, Stock Appears Fully Valued Rapid7 retreats as ARR outlook misses market expectations Rapid7 Non-GAAP EPS of $0.55 beats by $0...
BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leader in extended risk and threat detection, today announced the release of its 2024 Attack Intelligence Report . The report provides expert insights and guidance that security practitioners can use to better ...
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leader in extended risk and threat detection, today announced new, patented ransomware prevention technology that delivers end-to-end ransomware coverage to anticipate advanced attacks as well as accelerate det...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...
2024-07-09 22:15:01 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for RPD on July 9, 2024 09:06PM ET. The previous analyst recommendation was Equal-Weight. RPD was trading at $39.72 at issue of the analyst recommendation. The overall analyst consensus : BU...